Resmetirom
REZDIFFRA
Thyroid Hormone Receptor beta Agonist
NADAC/unit
N/A
No Shortage
Tier 1: 53.8%
PA Req: 298.2%
REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent w....
Generic Manufacturers
MADRIGAL PHARMACEUTICALS INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.